InMed Pharmaceuticals Inc. Announces Non-Brokered Private Placement - Video News Alert on InvestmentPitch.com

Vancouver, British Columbia--(Newsfile Corp. - November 6, 2015) - InMed Pharmaceuticals Inc. (CSE: IN) (OTCQB: IMLFF) has announced a non-brokered private placement of up to 6,666,667 units priced at $0.15 per unit for gross proceeds of up to $1 million, with the net proceeds to be used for general working capital purposes. Each unit will consist of one common share and one-half of a warrant, with each full warrant exercisable at $0.30 for a period of 12 months.

InvestmentPitch.com has produced a "video news alert" which provides a brief overview of the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter "InMed" in the search box.

If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_r6wyiqdd/InMed-Pharmaceuticals-Inc-CSEIN-OTCQBIMLFF-has-announced-a-non-brokered-private-placement

InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary drug discovery program seeks to identify a systems approach to treating diseases using known and as yet unknown genes identified using their proprietary bioinformatics process.

The company is currently working on two products in its development pipeline. INM-750 is for the treatment of Epidermolysis Bullosa, a serious pediatric orphan disease which affects approximately 25,000 patients in the U.S., and 500,000 globally. InMed has reported that INM-750 has demonstrated positive effects in pre-clinical studies on wound healing and in inflammation.

The second product, INM-085, is for the treatment of Glaucoma, the second leading cause of blindness in the developed world. 2.7 million people in the United States suffer from glaucoma, a number that is expected to reach 4.3 million by 2030.

The company's shares are trading at $0.15, and with 57.9 million shares outstanding, the company is capitalized at $8.7 million.

For more information, please visit the company's website www.inmedpharma.com, contact Paul Brennan, President & CEO, at 604-669-7207 or emailinfo@inmedpharma.com.

About InvestmentPitch

InvestmentPitch Media is arguably the largest producer and distributer of video content, primarily for small and mid-cap companies. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com